TRPV1 and hypertensive disorder: OLDA, given intrathecally to segments supplying the kidney, prevented HFD-induced impairment in TRPV1-positive afferent renal nerves, resulting in the restoration of the suppressive effects of ARNA on RSNA and the alleviation of renal dysfunction and hypertension.